Please assess the completion status of the following clinical trial:

Trial Title: The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnancy~* undergoing a Cesarean delivery via a transverse incision at York Hospital labor and delivery~* Documented history of chronic opioid use or documented OUD, or currently utilizing medically assisted treatment (MAT)~Exclusion Criteria:~* Patients with a history of clinically significant cardiovascular, hepatic, or renal disease~* Non-English speaking~* Allergy to bupivacaine, lidocaine, zinc, silver or menthol~* Unable to consent, due to lack of decisional capacity or need for emergent Cesarean delivery~* History of glucose-6-phosphate deficiency~* Use of anti-arrhythmic drugs such as tocainide or mexiletine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Lidoderm patch (Type: ACTIVE_COMPARATOR): Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
- Infusion pump (Type: ACTIVE_COMPARATOR): Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).